Introduction

Routine medical and ophthalmic care is being drastically curtailed in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Uveitis patients require particular attention because of their theoretical risk of viral infection, in the context of therapeutic immunosuppression.

Areas covered

This collaborative work proposes practical management and follow-up criteria for uveitis patients in the context of the ongoing SARS-CoV-2 pandemic.

Expert opinion

Management should proceed as usual when access to health care possible in patients who do not belong to a group at high risk of severe SARS-CoV-2 infection, and in uncontrolled uveitis cases. In case of reduced access to eye clinics or high risk of SARS-CoV-2 infection, patients’ management should be stratified based on their clinical presentation. In non-severe uveitis cases, the use of systemic steroids should be avoided, and local steroids preferred whenever possible. In uncontrolled situations where there is real risk of permanent visual loss, high-dose intravenous steroids and/or systemic immunosuppressants and/or biotherapies can be administered depending on the severity of eye disease. Immunosuppressive therapy should not be withheld, unless the patient develops SARS-CoV2 infection.

中文翻译：

---

有关SARS-CoV-2爆发期间葡萄膜炎患者管理和随访的专家意见。

介绍

在严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）大流行的情况下，常规医疗和眼科护理已被大大削减。在治疗性免疫抑制的背景下，葡萄膜炎患者需要特别注意，因为其理论上存在病毒感染的风险。

覆盖区域

在正在进行的SARS-CoV-2大流行的背景下，这项合作工作为葡萄膜炎患者提出了实用的管理和随访标准。

专家意见

如果不属于严重SARS-CoV-2严重感染高危人群的患者以及葡萄膜炎未得到控制，则应尽可能照常进行管理。如果减少就诊眼科诊所或SARS-CoV-2感染的高风险，应根据临床表现对患者的治疗进行分层。在非严重葡萄膜炎病例中，应避免使用全身性类固醇，并尽可能使用局部类固醇。在真正存在永久性视力丧失风险的无法控制的情况下，可根据眼部疾病的严重程度，服用大剂量静脉内类固醇和/或全身性免疫抑制剂和/或生物疗法。除非患者发展为SARS-CoV2感染，否则不应停止免疫抑制治疗。